Showing results (141-150 of 192) with videos related to
Sort By:
Pageof 20
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 7, 2010
Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time PCR and high-resolution melting curve analysisS N Anuj, D M Whiley, T J Kidd, et al.JAMA|July 14, 2011
Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trialClaire E Wainwright, Suzanna Vidmar, David S Armstrong, et al.The European Respiratory Journal|April 10, 2025
Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: Results from a 96-week open-label extension studyMarcus A Mall, Claire E Wainwright, Julian Legg, et al.European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 9, 2013
Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosisJ Manos, H Hu, B R Rose, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 24, 2020
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutationJane C Davies, Isabelle Sermet-Gaudelus, Lutz Naehrlich, et al.Journal of Medical Microbiology|April 28, 2021
Rapid macrolide and amikacin resistance testing for Mycobacterium abscessus in people with cystic fibrosisAmanda Bordin, Sushil Pandey, Christopher Coulter, et al.Thorax|February 5, 2004
Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional studyH M Buntain, R M Greer, P J Schluter, et al.Applied and Environmental Microbiology|July 10, 2007
Physical inactivation of Toxoplasma gondii oocysts in waterKatlyn E Wainwright, Manuel Lagunas-Solar, Melissa A Miller, et al.The Journal of Pediatrics|July 6, 2014
Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosisMarj Moodie, Anita Lal, Suzanna Vidmar, et al.American Journal of Respiratory and Critical Care Medicine|April 18, 2013
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutationJane C Davies, Claire E Wainwright, Gerard J Canny, et al.Pageof 20